1. Introduction {#s0005}
===============

The brain\'s function is thought to be dependent on coordinated activity in complex networks, with the goal of highly efficient information processing ([@bb0005]). With the advent of functional magnetic resonance imaging (fMRI), we have been provided opportunities to gain insights to neural networks in vivo. A growing number of studies suggest schizophrenia to be a disorder of brain network organization, with symptoms likely related to aberrant communication in networks of brain regions ([@bb0135]).

Resting state fMRI allows examination of intrinsic characteristics of brain networks, by assessing temporal covariation of low frequency fluctuations in the blood oxygen level dependent (BOLD) signal across all voxels in the brain, or functional connectivity ([@bb0055]). Several cortical resting state networks that are reproducible across different study populations have been identified. These include the dorsal attention network (DAN), executive control network (ECN), salience network, and default mode network (DMN). The DAN and ECN are engaged in higher-order cognitive and attentional control ([@bb0365], [@bb0120]). The salience network supports integrative processes ([@bb0300]) and the DMN has been associated with introspection and attention to internal states ([@bb0065], [@bb0325], [@bb0445]).

Large scale functional networks appear differentially affected ([@bb0470]), and increases, decreases, as well as lack of abnormalities in connectivity reported ([@bb0445], [@bb0455], [@bb0245], [@bb0130], [@bb0450], [@bb0285], [@bb0340]), for a summary of studies examining large scale network abnormalities at rest, please see [Table 1](#t0005){ref-type="table"}. The DMN is the most widely investigated large scale network in patients with schizophrenia. Some studies suggest hyperconnectivity of the DMN ([@bb0450], [@bb0485], [@bb0145]), while others find a mix of hyperconnectivity in posterior regions and hypoconnectivity in anterior regions of the network ([@bb0285], [@bb0250], [@bb0075]). An activation likelihood meta-analysis of DMN resting state studies in predominantly medicated patients with schizophrenia discovered hypoconnectivity in the posterior cingulate cortex, hippocampus, and medial prefrontal cortex, as well as hyperconnectivity in the lingual gyrus ([@bb0205]). Results are also variable in other large scale networks in schizophrenia. While one study reported no functional abnormalities in the ECN in antipsychotic-naïve, first episode schizophrenia patients ([@bb0230]), ECN connectivity has been found reduced in the dorsolateral prefrontal cortex ([@bb0470], [@bb0485]), possibly spanning to the parietal aspects of the network ([@bb0035]) in medicated patients. Salience network alterations in schizophrenia are inconsistent as well with reductions in connectivity in the anterior cingulate cortex and insula reported in the early stage of the illness ([@bb0320]), but increased anterior cingulate together with decreased insula connectivity described in the chronic stage ([@bb0470], [@bb0255]). Others reported intact within salience network connectivity ([@bb0470], [@bb0245]). Data is limited for the DAN in schizophrenia, but connectivity in this network may also be aberrant ([@bb0470]). High variability between studies may be due to several factors, including sample size, image acquisition and analyses methods, data quality, and clinical heterogeneity.

It is likely that differences in the patient population such as medication management may account for a portion of the variability in findings. However, few attempts have been made to characterize large scale functional networks at rest in unmedicated patients with schizophrenia and to examine systems-level effects of antipsychotic medication on these measures, despite evidence suggesting that functional network architecture is sensitive to neuromodulation ([@bb0095], [@bb0420], [@bb0360]). Dopamine targeting agents such as L-dopa, methylphenidate, and haloperidol have been shown to affect functional connectivity in healthy subjects ([@bb0095], [@bb0385], [@bb0100]). In patients with schizophrenia, our group has reported that abnormally low ventral tegmental area to thalamus connectivity observed in unmedicated patients was restored to more normal patterns after one week of treatment with risperidone ([@bb0150]). Sarpal and colleagues reported increases in connectivity between striatal seed regions and the thalamus in a group of first episode psychosis patients after twelve weeks of treatment with risperidone or aripiprazole and also reported changes in fronto-limbic to striatal connectivity as a function of good clinical response ([@bb0355]). Olanzapine has been reported to increase functional connectivity in DMN connectivity with the ventromedial prefrontal cortex, but not posterior regions of the DMN between weeks four and eight of treatment ([@bb0350]). Examining amplitudes of low frequency fluctuations (ALFF), another measure in functional connectivity, another group showed increased ALFF in prefrontal, parietal and temporal areas after six weeks of treatment with various second generation antipsychotic medications ([@bb0235]).

The purpose of this study was to better characterize systems-level effects of risperidone, a commonly prescribed second generation antipsychotic medication, on large scale resting state networks in schizophrenia. We obtained resting state scans before medication was initiated (in unmedicated subjects) and after six weeks of treatment to investigate antipsychotic effects on four large scale networks, the DAN, the ECN, the salience network, and the DMN. Based on the existing literature, we hypothesized large scale functional networks to be differentially affected in unmedicated patients and that network integrity would be, at least partially, restored after six weeks of antipsychotic treatment. We also conducted exploratory analyses to investigate associations between connectivity and clinical variables.

2. Material and methods {#s0010}
=======================

Unmedicated patients with schizophrenia or schizoaffective disorder (SZ) were recruited from various outpatient clinics, the inpatient unit and emergency room at the University of Alabama at Birmingham (UAB). Healthy controls (HC) matched on age, sex, parental occupation and smoking status were recruited by advertisements in flyers and the university\'s newspaper. Approval for this investigator-initiated study was obtained by the UAB Institutional Review Board. Written informed consent to participate in the study was obtained after subjects were deemed competent to provide consent ([@bb0085]).

Diagnoses were established by review of medical records and consensus of two clinicians and then confirmed with the Diagnostic Interview for Genetic Studies ([@bb0280]). All SZ were off antipsychotic medication for at least ten days and agreed to treatment; medication was not discontinued to meet this criterion. Subjects were excluded if they had a major medical or neurological condition, history of head trauma with loss of consciousness, met criteria for a moderate or severe substance use disorder other than nicotine use disorder within six months of imaging, were prescribed medications known to affect brain function, were pregnant or breastfeeding, or had any MRI contraindications. A personal or family history in a first-degree relative of an Axis I disorder was an exclusion criterion for HC.

Subjects who were either medication naïve or had been off antipsychotic medications were enrolled in a six week trial with risperidone using a flexible dosing regimen. Medication was managed by two psychiatrists (ACL and NVK), and dose determinations were based on therapeutic and side effects. Starting doses were 1--3 mg; titration was done in 1--2 mg increments. Compliance was monitored by pill counts at each visit. Concomitant antidepressant or mood stabilizing medication was allowed to be used as indicated. Resting state scans were obtained prior to treatment (off medication) and after six weeks of treatment with risperidone.

Of the 68 subjects enrolled, one HC was excluded from baseline analysis because of poor scan quality. In the SZ group 6 subjects dropped out of the study prior to the second scan. Additionally, no resting state data was available for 6 subjects at week 6 (resting state scans not obtained for 5 subjects, poor scan quality in 1 subject), leaving data for 34 SZ at baseline and 22 SZ at week 6 in the final analysis. Additionally, we scanned a group of 19 HC twice six weeks apart to give us the ability to assess connectivity changes over time. Resting state data from some subjects have been included in earlier reports ([@bb0150], [@bb0195]).

2.1. Clinical variables {#s0015}
-----------------------

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was used to characterize general cognitive function ([@bb0330]). The Brief Psychiatric Rating Scale (BPRS) was used for weekly assessments of symptom severity ([@bb0295]).

2.2. MRI acquisition {#s0020}
--------------------

All imaging was performed on a 3T head-only scanner (Magnetom Allegra, Siemens Medical Solutions), equipped with a circularly polarized transmit/receive head coil. Resting state fMRI scans were acquired during a five-minute gradient recalled echo-planar imaging sequence (repetition time/echo time \[TR/TE\] = 2000/30 msec, flip angle = 70°, field of view = 192 × 192 mm^2^, 64 × 64 matrix, 6-mm slice thickness, 1-mm gap, 30 axial slices, 150 acquisitions). During the scan, subjects were instructed to keep their eyes open and stare passively ahead. High-resolution structural scans were acquired using the three-dimensional T1-weighted magnetization prepared rapid acquisition gradient-echo sequence (TR/TE/inversion time \[TI\] = 2300/3.93/1100 msec, flip angle = 12°, 256 × 256 matrix, 1 mm isotropic voxels). All MRI scans were reviewed for abnormalities by a neuroradiologist.

2.3. Functional connectivity analysis {#s0025}
-------------------------------------

Using the statistical parametric mapping package SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK), resting state data were slice timing corrected, realigned using rigid-body motion transforms, co-registered to the high-resolution structural scan, normalized to 1.5 mm^3^ Montreal Neurologic Institute (MNI) space, and spatially smoothed employing the diffeomorphic anatomical registration using exponentiated lie algebra algorithm (DARTEL) with a 6-mm at full-width half-maximum three-dimensional Gaussian kernel ([@bb0030]).

To remove physiological noise from data, a nuisance regression was first conducted using the six motion parameters identified during the realignment step and their first derivatives as regressors. Next, a step-wise data scrubbing procedure was followed to reduce the effects of time points severely contaminated by motion ([@bb0310]). Framewise displacements from each time point, *i*, to the next (FD~*i*~) were computed from the six realignment parameters from SPM8. A radius r = 50 mm, approximately the mean distance from the center of MNI space to the cortex, was used to convert angle rotations (radians) to displacements (mm). Time points with FD~*i*~ \> 0.5 mm were considered to be severely contaminated with motion or other artifact. These contaminated time points were first interpolated prior to bandpass filtering of the data (0.009 \< f \< 0.08 Hz) ([@bb0080]), and then excluded from subsequent analyses ([@bb0315]). To assess motion effects on connectivity data, we calculated mean absolute framewise displacement of the brain from one timeframe to the next for each subject. There were no significant differences in mean absolute framewise displacement between HC and unmedicated SZ, or between time points in SZ (HC: 0.17 +/− 0.23 mm; SZ baseline: 0.23 mm +/− 0.23 mm; SZ week 1: 0.17 +/− 0.12 mm; SZ week 6: 0.23 mm +/− 0.23 mm; all p \> .05), however, more timepoints were scrubbed in SZ than HC (t = − 2.781; p \< .01). Following data scrubbing, a principle component analysis was used to extract the components of white matter and cerebral spinal fluid necessary to explain 90% of signal variance from those regions. These extracted components were used as regressors in a second nuisance regression ([@bb0045]).

Spherical seeds with 6 mm radius were placed at the following MNI coordinates to define resting state networks as described in previous studies ([@bb0365], [@bb0470], [@bb0425], [@bb0005]) − 25/− 53/52 and 25/− 57/52 (intraparietal sulcus and superior parietal lobe) for the DAN, ([@bb0135]) − 42/34/20 and 44/36/20 (left and right dorsolateral prefrontal cortex) for the ECN, ([@bb0055]) − 32/26/− 14 and 38/22/− 10 (left and right fronto-insular cortex) for the salience network, and ([@bb0365]) 1/− 55/17 (posterior cingulate cortex) for the DMN.

The first eigenvariate of the BOLD time series from each seed was extracted and correlated to the time series of all other voxels in the brain to produce functional connectivity maps (units of Pearson\'s *r* correlation). For networks with bilateral seeds, these were averaged to form a single functional connectivity map of each network for each subject. Maps were converted to normally distributed values using Fisher\'s *r*-to-Z transform.

Group-level functional connectivity maps were obtained by performing one-sample *t*-tests on each group\'s participant-level functional connectivity maps. Group differences in functional connectivity, as well as differences between medication-naïve and previously medicated patients, were assessed using two-sample *t*-tests on the groups\' participant-level functional network connectivity maps. To restrict analyses to include only those brain regions that were recruited by at least one of the groups, we created thresholded t-maps (*P*~FDR~ \< .01) combining groups. We computed these by creating one-sample t-tests for each resting state network and both diagnostic groups (both points in SZ) that were binarized and combined, thus producing masks of the combined connected areas. These masks were used in between group comparisons and comparisons across time within each large scale network. All analyses were corrected for multiple comparisons using the false discovery rate and are reported at *P*~FDR~ \< 0.001 for main effects within group and at *P*~FDR~ \< 0.05 for group differences and change over time.

To assess connectivity changes over time in healthy controls we implemented two statistical tests. First, we used paired-sample t-tests on the participant-level functional network connectivity maps for each network to examine change over time at the group level. Second, we calculated intra-subject reliability at the network level implemented in the ICC toolbox (<http://brainmap.co.uk>). Intra voxel intra-class correlation coefficients (ICC) were calculated for each subject using the contrast values of the voxels within the networks. The median ICC and standard errors were obtained from a bootstrapped ICC distribution with 1000 re-samples per subject ([@bb0070]).

In an exploratory fashion, we also examined the relationships between connectivity and clinical variables. To assess the relationship between functional connectivity of each network and symptom burden at baseline in patients with schizophrenia, we used a general linear model that included BPRS total scores and one that included RBANS total scores. To restrict analyses to each network, above described masks were used in the general linear model. Treatment response was defined as (BPRS positive score at baseline − BPRS positive score at 6 weeks) / BPRS positive score at baseline. We were able to assess treatment response for 28 subjects at week 6, and carried forward week 5 data from two subjects, totaling of 30 subjects with treatment response scores.

3. Results {#s0030}
==========

3.1. Demographics and behavioral results {#s0035}
----------------------------------------

Of the 34 SZ subjects, 22 were chronically ill and 12 experienced their first episode. 17 SZ were antipsychotic naïve (five had not received prior treatment despite a prolonged period since illness onset), and 17 have had prior exposure to antipsychotic medication. Average dose of risperidone at endpoint was 4.36 +/− 1.45 mg. Twelve subjects were concomitantly treated with benztropine, two with trazodone, one each was prescribed mirtazapine, amitriptyline, and valproic acid.

There were no significant differences between HC and SZ in age, sex, parental socioeconomic status, or smoking status ([Table 2](#t0010){ref-type="table"}). As expected, SZ scored significantly lower on the RBANS compared to HC. In SZ, BPRS total scores decreased from 48.29 +/− 9.38 at baseline to 30.57 +/− 8.47 after six weeks of treatment.

3.2. Imaging results {#s0040}
--------------------

### 3.2.1. Functional connectivity in HC and unmedicated SZ {#s0045}

In HC, analyses revealed functional network architecture of all four large scale networks consistent with prior reports ([Fig. 1](#f0005){ref-type="fig"}); connectivity patterns at the group level did not significantly change between baseline and week six in any of the networks in the 19 HC scanned twice. Median intra-voxel ICC in HC between the two scans was 0.44 +/− 0.03 for the DAN, 0.35 +/− 0.07 for the ECN, 0.38 +/− 0.08 for the salience network, and 0.33 +/− 0.07 for the DMN.

In unmedicated SZ, we found increased functional connectivity in the DAN, ECN, and salience networks, but not the DMN when compared to HC ([Fig. 2](#f0010){ref-type="fig"}). There were no areas of decreased connectivity in any of the resting state networks. Connectivity patterns did not significantly differ between the 17 medication naïve and 17 previously medicated SZ in any network. DAN connectivity was increased in the angular gyrus, middle temporal gyrus, superior and inferior parietal gyri, cuneus/precuneus, superior and middle occipital gyrus, and calcarine sulcus. In the ECN, we noted elevated connectivity in the superior frontal, middle frontal, and inferior frontal gyri, supplemental motor cortex, as well as anterior and middle cingulate cortices. Connectivity was also increased in the rolandic operculum, insula, basal ganglia and amygdala in the salience network ([Table 3](#t0015){ref-type="table"}). Using more stringent corrections we found that ECN connectivity to the inferior frontal gyrus was increased (*t* = 4.37, *P*~FDR~ \< .01, k~E~ \[cluster extent, number of voxels\] = 493, MNI coordinates: *x* = − 30, *y* = 52, *z* = 14), but we no longer found increased connectivity in the DAN or salience networks. To better understand the increase in connectivity (and because the number of voxels functionally connected to the seed region was 11% higher in the DAN and 17% higher in the ECN, salience network, and DMN in unmedicated SZ compared to HC), we conducted a post-hoc analysis limiting analyses of connectivity differences between HC and unmedicated SZ only to areas included in HC network (i.e. all voxels that functionally connected to the seed in HC). We found no abnormalities in any of the networks (all *P*~FDR~ \> .05) or differences in mean signal amplitude (DAN: t = − 0.102; p = .91; ECN: t = − 0.293; p = .77; salience network: t = 1.357; p = .18; DMN: t = 0.544; p = .59), suggesting that the increase in functional connectivity seen in SZ may be related to topographical expansion of large scale networks rather than abnormally increased connectivity within areas that are typically part of the networks.

### 3.2.2. Relationship between abnormalities in large scale networks and symptom burden {#s0050}

Exploratory analyses to investigate associations between connectivity and clinical variables were also conducted. We found that higher BPRS total scores in unmedicated SZ were related to higher DMN functional connectivity strength in one cluster in the bilateral precuneus/posterior cingulate cortex (t = 3.86, *P*~FDR~ \< .05, k~E~ = 2029, MNI coordinates: *x* = 0, *y* = − 72, *z* = 39; [Fig. 3](#f0015){ref-type="fig"}), but this association was not unique to symptom dimension. Lower RBANS scores were associated with higher salience network connectivity strength in one cluster in the right insula and inferior frontal cortex (t = 5.61, *P*~FDR~ \< .05, k~E~ = 2665, MNI coordinates: *x* = 34, *y* = 30, *z* = − 4; [Fig. 3](#f0015){ref-type="fig"}), no relationship between RBANS scores and salience network connectivity strength was found in HC. Greater baseline DAN connectivity in two clusters spanning the cuneus/precuneus, superior and inferior parietal lobes, lingual gyrus, middle occipital lobe, and calcarine sulcus was associated with eventual clinical response at week six (Cluster 1: t = 4.91, *P*~FDR~ \< .05, k~E~ = 1677, MNI coordinates: *x* = 8, *y* = − 34, *z* = 51; Cluster 2: t = 4.42, *P*~FDR~ \< .05, k~E~ = 2701, MNI coordinates: *x* = − 36, *y* = − 84, *z* = 20; [Fig. 4](#f0020){ref-type="fig"}).

### 3.2.3. Change in functional connectivity over time with risperidone treatment {#s0055}

We observed resting state functional connectivity changes after six weeks of treatment with risperidone only in the DAN, but none of the other networks. Contrasting baseline and week six of treatment, an overall decrease in connectivity was seen in the lingual gyrus, fusiform gyrus, precuneus, calcarine sulcus and cerebellum. No areas within the DAN showed increased connectivity compared to baseline ([Table 4](#t0020){ref-type="table"}, [Fig. 4](#f0020){ref-type="fig"}). Using more stringent corrections (*P*~FDR~ \< .01) we observed no change in connectivity over time in the DAN. Median intra-voxel ICC in SZ between the two scans was 0.48 +/− 0.06 for the DAN, 0.38 +/− 0.03 for the ECN, 0.36 +/− 0.06 for the salience network, and 0.70 +/− 0.04 for the DMN.

4. Discussion {#s0060}
=============

To our knowledge, this is the first longitudinal study characterizing four large-scale brain networks in unmedicated patients with schizophrenia and the effects of risperidone on resting state functional connectivity. We report functional architecture of each network in healthy controls that is principally consistent with the existing literature and show increased resting state connectivity in the DAN, ECN, and salience networks, but not DMN, in unmedicated patients; abnormalities did not differ between medication-naïve subjects and those with prior exposure to antipsychotic medications. Additionally, we demonstrate attenuation of dysconnectivity in the DAN after six weeks of treatment with risperidone and a possible link between baseline DAN connectivity strength and eventual clinical response.

Our findings are in agreement with the concept of schizophrenia as a disorder of brain network organization and a prior report of resting state networks being differentially affected in schizophrenia ([@bb0470]). A number of studies suggest widespread abnormalities in large scale networks in schizophrenia ([@bb0175], [@bb0260], [@bb0375], [@bb0290], [@bb0275], [@bb0465]), but disturbances vary by network, and neither directionality (increase or decrease) nor spatial patterns of dysconnectivity appear consistent ([@bb0455], [@bb0480]). For example, Rotarska-Jagiela and colleagues who reported decreased DMN connectivity and increased ECN connectivity to the left parietal cortex in patients with schizophrenia compared to healthy controls, but observed no group differences in other large scale networks ([@bb0345]). In a large group of medication-naïve first episode schizophrenia patients, resting state ALLFs were found to be decreased in areas of the DMN and ECN ([@bb0335]). Examining topological properties of functional network connectivity using graph metrics, another study reports abnormalities in areas of the brain that are typically conceptualized as part of the DMN, ECN, and motor network in medicated patients with schizophrenia compared to healthy controls ([@bb0475]). We report an increase in resting state connectivity in networks that typically show activation in response to goal directed tasks. The negative correlation between salience network connectivity strength and RBANS scores is consistent with prior reports linking aberrant connectivity in this network with information processing deficits in schizophrenia ([@bb0440]). Similar to Baker et al. who examined resting state ECN integrity across the psychosis spectrum, we did not see a relationship between connectivity disruption and clinical variables ([@bb0035]). Somewhat surprisingly, we did not observe dysconnectivity in the DMN, a network that is often reported abnormal in medicated patients with schizophrenia ([@bb0455]), and possibly even in unaffected relatives of patients with schizophrenia ([@bb0265], [@bb0090]) \[but also see ([@bb0465]), which did not find aberrant DMN connectivity\]. To our knowledge, all resting state studies examining the DMN to date have enrolled medicated subjects, which may explain discrepancies in findings.

Our findings suggest that increased network connectivity seen in unmedicated patients with schizophrenia may be related to topographical expansion of networks. Examining the spatial extent of resting state networks, wider connectivity in the ECN and greater spatial dispersion of the DMN in schizophrenia compared to healthy controls have been reported ([@bb0470], [@bb0220]). However, the cellular level mechanisms of aberrant resting state connectivity remain unclear. Postmortem studies report abnormalities in both excitatory and inhibitory neuronal components, such as reduced NMDA-receptor expression ([@bb0050]), disrupted glutamate transport protein complex integrity ([@bb0370]), reductions in parvalbumin containing interneurons ([@bb0210]), and lower glutamic-acid-decarboxylase levels, the rate-limiting enzyme of GABA production ([@bb0010]). Disruption in the excitation/inhibition balance may lead to increase of excitability in cortical microcircuitry, impact connectivity in large-scale networks, and result in behavioral abnormalities ([@bb0200], [@bb0415], [@bb0110]). Consistent with this, administration of ketamine, a NMDA receptor antagonist, has been found to globally increase functional connectivity during rest ([@bb0125]). In a complementary experiment, examining large scale networks during a working memory task, Anticevic and colleagues demonstrated a disruption in the reciprocal relationship between networks and interpreted this as evidence of cortical disinhibition secondary to NMDA receptor hypofunction ([@bb0025]). In light of these findings, it is tempting to speculate that the increase in connectivity we see in schizophrenia could be secondary to an aberrant excitation/inhibition balance.

Our findings extend the existing literature by showing that risperidone, a commonly prescribed antipsychotic medication, may affect resting state functional connectivity in patients with schizophrenia. Thus far, the majority of studies have considered antipsychotic medications as confounding variable rather than modulating factor. Only few studies have explicitly investigated systems-level effects of antipsychotic medications on resting state connectivity. Lui et al. examined connectivity in medication-naïve, first-episode patients using seven seed regions defined as areas in which patients showed abnormalities in regional amplitudes of low frequency fluctuations (ALFF), a different measure of spontaneous synchronous neuronal activity. They report the impact of antipsychotics to be rather non-specific, restoring connectivity patterns in some areas but also affecting connectivity to areas that were not altered before treatment ([@bb0240]). Our group recently examined the effects of risperidone on resting state connectivity patterns of ventral tegmental area (VTA), the origin of mesocorticolimbic dopamine projections and reported that risperidone partially attenuates VTA dysconnectivity after one week of treatment. Interestingly, we had found that connectivity between the VTA and DMN as well as the dorsal anterior cingulate cortex at baseline, while unmedicated, correlated with eventual clinical response to medication ([@bb0150]). Now, we again report a relationship between functional connectivity (in this case the DAN) in unmedicated patients and eventual clinical response to antipsychotic medication. In a recent seed-based resting state study with a similar clinical design to ours, Sarpal and colleagues have examined longitudinal effects of treatment with second generation antipsychotic medications (risperidone and aripiprazole) on striatum functional connectivity in patients with first episode psychosis and report a cortico-striatal connectivity increase as a function of clinical symptom improvement ([@bb0355]). Contrasting to our study, the authors did not find differences in connectivity at baseline between patients and healthy controls, which may due to not all of their subjects having an antipsychotic free interval prior to the baseline scan.

Our finding of attenuation in DAN hyperconnectivity with medication is consistent with recent drug challenge studies demonstrating that dopamine antagonism may reduce connectivity in task positive networks ([@bb0095]). The DAN controls goal-oriented, top-down deployment of attention. In medication-naïve patients with schizophrenia, reduced activation of the DAN during an antisaccade task has been reported to be partially restored by risperidone ([@bb0165]). One may speculate that the extent of increased functional connectivity in the DAN may reflect the system\'s ability to maintain integrated (mal)adaptive functional systems and neuroplasticity, and thus be related to better treatment response ([@bb0140]). Though it remains unclear how antipsychotic drugs modulate functional connectivity, several mechanisms have been proposed. Antipsychotic medications principally act via blockage of the dopamine D~2~ receptor. However, it is unlikely that observed changes were due solely to changes in dopaminergic transmission, given the indirect nature of the BOLD response in relation to neuronal activity ([@bb0225]). Evidence from both cross-sectional and longitudinal studies suggests that abnormally elevated glutamate levels may decrease with antipsychotic treatment, potentially attenuating excitation/inhibition imbalances and restoring functional connectivity ([@bb0185], [@bb0190], [@bb0105], [@bb0170]). Work in animal models suggests that antipsychotics may have effects on white matter volumes, myelination, and numbers of oligodendrocytes ([@bb0040], [@bb0115], [@bb0180]). Consistent with this, diffusion tensor imaging (DTI) studies in first episode schizophrenia report a decrease in fractional anisotropy (FA), a marker of white matter structural integrity, after twelve weeks of treatment with antipsychotic medication ([@bb0400]). It is possible that some of the changes in functional networks seen with treatment are secondary to antipsychotic induced changes in underlying structural networks.

Of course, our results have to be interpreted in context of several limitations. Resting state functional MRI is prone to contamination by head motion and non-neuronal signals such as heart beat. To minimize the chance of spurious correlations, we used well-validated preprocessing techniques and motion "scrubbing". Medication compliance was monitored with pill counts at each visit, but we did not have serum risperidone levels available to confirm adherence. Also, because known effective treatments cannot be withheld, we did not have a placebo group in this study, rendering it impossible to definitively attribute DAN connectivity changes over six weeks in the SZ group to medication effects rather than time, or lack of stability/reliability in functional connectivity measures. However, given that we did not find significant functional connectivity changes in the subgroup of HC we scanned twice six weeks apart and that within network test-retest reliability was fair to high ([@bb0430]), it is likely that changes seen in patients are due to effects of treatment. Our SZ group included five subjects who were chronically ill, but had no prior exposure to antipsychotic treatment. Because of the limited number of subjects, we were unable to examine connectivity patterns in this subgroup, but it will be important for future studies to determine if patients with an extended duration of untreated psychosis are more similar to medication-naïve subjects with shorter illness duration or to chronically ill patients with prior exposure to antipsychotics. An unresolved issue in the literature lays in accounting for multiple comparisons when using several seed regions. We attempted to mitigate this by limiting comparisons to voxels that were recruited by their respective networks, substantially reducing the likelihood of type I errors. However, future studies are warranted to investigate the replicability of our findings.

In summary, our results demonstrate abnormalities in large scale functional networks in patients with schizophrenia that are modulated by risperidone only to a certain extent, highlighting the need for development of novel antipsychotic medications that have the ability to alleviate symptoms through attenuation of dysconnectivity. Given the considerable overlap in clinical presentation and management across the spectrum of psychotic disorders, it would be important for future studies to examine if antipsychotic medication effects on connectivity are specific to schizophrenia or extend to other diagnostic constructs.
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![Resting state networks in healthy controls (HC; n = 33; left column) and unmedicated patients with schizophrenia (SZ baseline; n = 34; right column). Statistical maps are significant at *P*~FDR~ \< .001. Results are projected on BrainNet Viewer surface map, medium view. Abbreviations: DAN: dorsal attention network; ECN: executive control network; DMN: default mode network; L: left; R: right.](gr1){#f0005}

![Resting state connectivity abnormalities in unmedicated patients with schizophrenia (n = 34) compared to healthy controls (n = 33). Clusters indicate areas with significantly increased connectivity in unmedicated patients compared to controls. No clusters with decreased connectivity in unmedicated patients compared to controls are present. Statistical maps are significant at *P*~FDR~ \< .05. Clusters are overlaid on the Xjview single subject T1 template, left columns show a sagittal slice, all others are axial. Numbers below the slices indicate x and z coordinates in MNI convention. Color bar indicates t values. Abbreviations: DAN: dorsal attention network; ECN: executive control network.](gr2){#f0010}

![Dorsal attention network connectivity, effects of risperidone and treatment response. Top row: Clusters indicate regions where connectivity strength in unmedicated patients with schizophrenia is related to clinical response after six weeks of treatment with risperidone (n = 30). Bottom row: Clusters indicate regions showing changes in functional connectivity in patients with schizophrenia between baseline and week 6 (n = 22). Statistical maps are significant at *P*~FDR~ \< .05. Clusters were overlaid on the Xjview single subject T1 template, left columns show a sagittal slice, all others are axial. Numbers below the slices indicate x and z coordinates in MNI convention. Color bar indicated t values. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr3){#f0015}

![Relationship between resting state functional connectivity and clinical variables in patients with schizophrenia (n = 34). Left: Clusters indicate regions where connectivity strength within the network where is correlated with symptom severity. Statistical maps are significant at *P*~FDR~ \< .05. Clusters are overlaid on the Xjview single subject T1 template, left column shows a sagittal slice, middle column shows an axial slice. Numbers below the slices indicate x and z coordinates in MNI convention. Color bar indicates t values. Right: Correlations between baseline functional connectivity strength and symptom severity. Abbreviations: DMN: default mode network; BPRS: Brief Psychiatric Rating Scale; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)](gr4){#f0020}

###### 

Resting state fMRI studies examining abnormalities in large-scale networks in schizophrenia.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Year   Sample size (HC/SZ)   Medication status                    Illness stage   Field strength (Tesla)   Length of scan (min)   Eyes open/closed   Analysis type        Results
  --------------------------- ------ --------------------- ------------------------------------ --------------- ------------------------ ---------------------- ------------------ -------------------- -----------------------------------------
  Dorsal attention network                                                                                                                                                                              

  ([@bb0215])                 2015   103/121               Medication-naïve/minimally treated   First episode   3                        6.6                    Closed             ICA                  No group differences

  ([@bb0470])                 2012   61/42                 Medicated                            Chronic         3                        7                      Closed             Seed based           HC \> SZ

                                                                                                                                                                                                        

  Executive control network                                                                                                                                                                             

  ([@bb0035])                 2014   100/60                Medicated (4 off medication)         Chronic         3                        6.2                    Open               Seed based           HC \> SZ

  ([@bb0090])                 2014   25/25                 Medicated (6 off medication)         Chronic         1.5                      6                      Closed             ICA                  Mixed increase and decrease in SZ

  ([@bb0175])                 2013   118/70                Medicated                            Chronic         3                        5.25                   Open               ICA                  No group differences

  ([@bb0215])                 2015   103/121               Medication-naïve/minimally treated   First episode   3                        6.6                    Closed             ICA                  No group differences

  ([@bb0220])                 2015   43/43                 Medicated                            Chronic         1.5                      8.4                                       ICA                  SZ \> HC

  ([@bb0240])                 2010   34/34                 Medication-naïve                     First episode   3                        6.6                                       ICA                  SZ \> HC

  ([@bb0245])                 2013   33/25                 Medicated                            Chronic         3                        13.7                   Closed             Seed based           No group differences

  ([@bb0255])                 2014   20/18                 Medicated\                           Chronic         3                        10                     Closed             ICA                  HC \> SZ frontal and parietal lobe;\
                                                           (2 off medication)                                                                                                                           SZ \> HC temporal and occipital lobe

  ([@bb0340])                 2011   15/25                 Medicated                            Chronic         3                        13.7                   Closed             Seed based           No group differences

  ([@bb0345])                 2010   16/16                 Medicated                            Chronic         3                        6.6                    Open               ICA                  HC \> SZ frontal gyrus,\
                                                                                                                                                                                                        SZ \> HC parietal cortex

  ([@bb0390])                 2013   25/25                 Medicated                            Chronic         3                        8.4                                       Seed based           HC \> SZ

  ([@bb0410])                 2013   36/36                 Medicated                            Chronic         3                        8.5                    Open               Seed based           HC \> SZ

  ([@bb0465], [@bb0460])      2011   14/10                 Medicated                            Chronic         3                        6                      Closed             ICA                  HC \> SZ to precuneus,\
                                                                                                                                                                                                        SZ \> HC to frontal lobe

  ([@bb0470])                 2012   61/42                 Medicated                            Chronic         3                        7                      Closed             Seed based           HC \> SZ in frontal regions

  ([@bb0490])                 2007   17/17                 Minimally treated                    First episode   1.5                      6                      Closed             Seed based           Mixed increase and decrease in SZ

  ([@bb0485])                 2007   18/18                 Medicated\                           Recent onset    1.5                      6                      Closed             Seed based           SZ \> HC in frontal regions,\
                                                           (3 off medication)                                                                                                                           HC \> SZ in insula and parietal lobe

                                                                                                                                                                                                        

  Default mode network                                                                                                                                                                                  

  ([@bb0015])                 2012   19/19                 Medicated\                           First episode   3                        2.6                    Closed             Seed based           HC \> SZ
                                                           (2 off medication)                                                                                                                           

  ([@bb0020])                 2015   20/33                 Medicated                            Chronic         3                        6                      Closed             Seed based           Mixed increase and decrease in SZ

  ([@bb0060])                 2007   17/17                 Medicated\                           Chronic         4                        5.5                    Closed             Seed based           HC \> SZ
                                                           (2 off medication)                                                                                                                           

  ([@bb0075])                 2011   29/29                 Medicated\                           Chronic         3                        6                                         ICA                  HC \> SZ
                                                           (2 off medication)                                                                                                                           

  ([@bb0090])                 2014   25/25                 Medicated\                           Chronic         1.5                      6                      Closed             ICA                  SZ \> HC
                                                           (6 off medication)                                                                                                                           

  ([@bb0145])                 2015   50/49                 Medication-naïve                     First episode   3                        8.3                    Closed             Seed based           SZ \> HC

  ([@bb0160])                 2008   25/29                 Medicated                            Chronic         3                        5                                         ICA                  Within network differences not reported

  ([@bb0155])                 2013   113/115               Medication-naïve                     First episode   3                        6.6                    Closed             Seed based           No group differences

  ([@bb0175])                 2013   118/70                Medicated                            Chronic         3                        5.25                   Open               ICA                  HC \> SZ

  ([@bb0215])                 2015   103/121               Medication-naïve/minimally treated   First episode   3                        6.6                    Closed             ICA                  SZ \> HC

  ([@bb0220])                 2015   43/43                 Medicated                            Chronic         1.5                      8.4                                       ICA                  SZ \> HC

  ([@bb0240])                 2010   34/34                 Medication-naïve                     First episode   3                        6.6                                       ICA                  HC \> SZ

  ([@bb0245])                 2013   33/25                 Medicated                            Chronic         3                        13.7                   Closed             Seed based           No group differences

  ([@bb0250])                 2010   16/16                 Medicated                            Chronic         1.5                      8                                         ICA and seed based   SZ \> HC in posterior regions,\
                                                                                                                                                                                                        HC \> SZ in frontal regions

  ([@bb0255])                 2014   20/18                 Medicated\                           Chronic         3                        10                     Closed             ICA                  HC \> SZ
                                                           (2 off medication)                                                                                                                           

  ([@bb0260])                 2012   118/70                Medicated                            Chronic         3                        5.25                   Open               ICA                  Within network differences not reported

  ([@bb0260], [@bb0265])      2014   324/296               Medicated\                           Chronic         3                        5                      Open               ICA                  HC \> SZ
                                                           (11 off medication)                                                                                                                          

  ([@bb0270])                 2012   25/25                 Medicated                            Chronic         3                        9                      Closed             ICA                  Mixed increase and decrease in SZ

  ([@bb0285])                 2010   15/14                 Medicated                            Chronic         3                        10                     Open               ICA                  HC \> SZ in the ACC;\
                                                                                                                                                                                                        SZ \> HC in basal ganglia

  ([@bb0290])                 2013   26/26                 Medicated                            Chronic         3                        8                      Closed             ICA                  HC \> SZ

  ([@bb0340])                 2011   15/25                 Medicated                            Chronic         3                        13.7                   Closed             Seed based           No group differences

  ([@bb0345])                 2010   16/16                 Medicated                            Chronic         3                        6.6                    Open               ICA                  HC \> SZ

  ([@bb0380])                 2010   27/27                 Medicated                            Chronic         3                        5.25                                      Seed based           SZ \> HC

  ([@bb0395])                 2011   28/28                 Medicated                            Chronic         3                        5                                         ICA                  Differences in network laterality

  ([@bb0405])                 2013   32/32                 Medicated\                           Early onset     1.5                      6                      Closed             ICA                  SZ \> HC
                                                           (6 off medication)                                                                                                                           

  ([@bb0435])                 2015   53/55                 Medicated\                           First episode   3                        8                      Closed             ICA                  SZ \> HC
                                                           (34 drug naïve)                                                                                                                              

  ([@bb0450])                 2009   13/13                 Medicated\                           Chronic         1.5                                                                Seed based           SZ \> HC
                                                           (3 off medication)                                                                                                                           

  ([@bb0460])                 2011   14/10                 Medicated                            Chronic         3                        6                      Closed             ICA                  No group differences

  ([@bb0470])                 2012   61/42                 Medicated                            Chronic         3                        7                      Closed             Seed based           SZ \> HC

  ([@bb0485])                 2007   18/18                 Medicated\                           Recent onset    1.5                      6                      Closed             Seed based           SZ \> HC
                                                           (3 off medication)                                                                                                                           

                                                                                                                                                                                                        

  Salience network                                                                                                                                                                                      

  ([@bb0215])                 2015   103/121               Medication-naïve/minimally treated   First episode   3                        6.6                    Closed             ICA                  No group differences

  ([@bb0245])                 2013   33/25                 Medicated                            Chronic         3                        13.7                   Closed             Seed based           No group differences

  ([@bb0255])                 2014   20/18                 Medicated\                           Chronic         3                        10                     Closed             ICA                  HC \> SZ in insula;\
                                                           (2 off medication)                                                                                                                           SZ \> HC in frontal regions

  ([@bb0275])                 2013   44/44                 Medicated                            Chronic         3                        5                      Open               Seed based           HC \> SZ

  ([@bb0290])                 2013   26/26                 Medicated                            Chronic         3                        8                      Closed             ICA                  HC \> SZ

  ([@bb0305])                 2013   35/38                 Medicated\                           Chronic         3                        10                     Open               Seed based           Mixed increase and decrease in SZ
                                                           (2 off medication)                                                                                                                           

  ([@bb0320])                 2012   90/90                 Medicated\                           Recent onset    1.5                      6                      Closed             Seed based           HC \> SZ
                                                           (16 drug naïve)                                                                                                                              

  ([@bb0470])                 2012   61/42                 Medicated                            Chronic         3                        7                      Closed             Seed based           No group differences
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Demographics and clinical measures.[a](#tf0005){ref-type="table-fn"}

                                                         SZ (n = 34)     HC (n = 34)      t/X^2^   p value
  ------------------------------------------------------ --------------- ---------------- -------- ---------
  Gender (% male)                                        67.6            67.6             0.000    1.0
  Age                                                    32.38 (10.43)   32.00 (9.02)     −.382    .87
  Parental occupation[b](#tf0010){ref-type="table-fn"}   7.26 (6.39)     6.21 (4.35)      − 0.80   .43
  Smoking status (% smokers)                             76.5            64.7             1.133    .42
  Smoking (packs per day)                                0.59 (0.53)     0.65 (0.60)      0.447    .66
  Diagnosis                                                                                        
   Schizophrenia                                         31                                        
   Schizoaffective disorder                              3                                         
  Illness characteristics                                                                          
   Illness duration (years)                              9.59 (9.94)                               
   First episode                                         12                                        
  Prior antipsychotic treatment                                                                    
   Antipsychotic naive                                   17                                        
   Antipsychotic free interval (months)                  23.08 (44.41)                             
  BPRS[c](#tf0015){ref-type="table-fn"}                                                            
   Total                                                                                           
   Baseline                                              48.29 (9.38)                              
   Week 6[d](#tf0020){ref-type="table-fn"}               30.57 (8.47)                              
   Positive                                                                                        
   Baseline                                              9.53 (3.04)                               
   Week 6[d](#tf0020){ref-type="table-fn"}               4.86 (2.38)                               
   Negative                                                                                        
   Baseline                                              6.79 (2.51)                               
   Week 6[d](#tf0020){ref-type="table-fn"}               5.39 (2.42)                               
  RBANS[e](#tf0025){ref-type="table-fn"}                                                           
   Total index                                           70.21 (13.76)   94.47 (13.99)    6.773    \<.01
   Immediate memory                                      74.68 (16.86)   96.53 (12.78)    4.962    \<.01
   Visuospatial                                          71.41 (15.48)   89.18 (19.15)    5.549    \<.01
   Language                                              84.71 (12.85)   96.68 (13.92)    3.663    \<.01
   Attention span                                        79.03 (20.32)   100.82 (18.92)   5.001    \<.01
   Delayed memory                                        72.53 (19.10)   93.53 (11.72)    5.348    \<.01

SZ, schizophrenia; HC, healthy control.

Mean (SD) unless indicated otherwise.

Ranks determined from Diagnostic Interview for Genetic Studies (1--18 scale); higher rank (lower numerical value) corresponds to higher socioeconomic status.

Brief Psychiatric Rating Scale (1--7 scale); positive (conceptual disorganization, hallucinatory behavior, and unusual thought content); negative (emotional withdrawal, motor retardation, and blunted affect).

n = 28.

Repeatable Battery for the Assessment of Neuropsychological Status.

###### 

Increased functional connectivity in unmedicated patients with schizophrenia compared to healthy controls.

  Brain regions                          Voxels in cluster   Hem.   Voxels in region   Peak coordinates[a](#tf0030){ref-type="table-fn"}   Peak *t*   *P*~FDR~[b](#tf0035){ref-type="table-fn"}           
  -------------------------------------- ------------------- ------ ------------------ --------------------------------------------------- ---------- ------------------------------------------- ------- --
  Dorsal attention network                                                                                                                                                                                
   Cluster 1                             2971                                          24                                                  − 54       51                                          3.891   
   Superior parietal gyrus                                   B      468                                                                                                                                   
   Inferior parietal gyrus                                   B      228                                                                                                                                   
   Cuneus/precuneus                                          B      665                                                                                                                                   
   Superior and middle occipital gyrus                       L      534                                                                                                                                   
   Cluster 2                             2234                                          15                                                  − 70.5     31.5                                        3.673   
   Middle temporal gyrus                                     R      119                                                                                                                                   
   Angular gyrus                                             R      56                                                                                                                                    
   Superior parietal gyrus                                   R      66                                                                                                                                    
   Cuneus/precuneus                                          R      741                                                                                                                                   
   Superior and middle occipital gyrus                       R      701                                                                                                                                   
   Calcarine sulcus                                          R      174                                                                                                                                   
  Executive control network                                                                                                                                                                               
   Cluster 1                             1450                                          − 30                                                52.5       13.5                                        4.369   
   Superior frontal gyrus                                    L      141                                                                                                                                   
   Middle frontal gyrus                                      L      1195                                                                                                                                  
   Inferior frontal gyrus                                    L      109                                                                                                                                   
   Cluster 2                             1344                                          − 9                                                 31.5       30                                          3.779   
   Superior medial frontal gyrus                             B      364                                                                                                                                   
   Supplemental motor area                                   B      77                                                                                                                                    
   Anterior cingulate cortex                                 B      269                                                                                                                                   
   Middle cingulate cortex                                   L      734                                                                                                                                   
  Salience network                                                                                                                                                                                        
   Cluster                               2615                                          34.5                                                − 13.5     12                                          4.613   
   Rolandic operculum                                        R      118                                                                                                                                   
   Pallidum/putamen                                          B      765                                                                                                                                   
   Caudate                                                   B      580                                                                                                                                   
   Insula                                                    R      253                                                                                                                                   
   Amygdala                                                  R      32                                                                                                                                    
  Default mode network                                                                                                                                                                                    
   No clusters                                                                                                                                                                                            

Abbreviations: Hem., hemisphere; L, left; R, right.

Reported in Montreal Neurologic Institute coordinates (X, Y, and Z).

All comparisons were FDR-corrected (*P*~FDR~ ≤ 0.05).

###### 

Change in dorsal attention network functional connectivity over six weeks of treatment with risperidone.

  Brain regions        Voxels in cluster   Hem.   Voxels in region   Peak coordinates[a](#tf0040){ref-type="table-fn"}   Peak *t*   *P*~FDR~[b](#tf0045){ref-type="table-fn"}           
  -------------------- ------------------- ------ ------------------ --------------------------------------------------- ---------- ------------------------------------------- ------- --
  Baseline \> week 6                                                                                                                                                                    
   Cluster             1454                                          − 6                                                 − 64.5     − 9                                         4.217   
   Lingual gyrus                           B      754                                                                                                                                   
   Fusiform gyrus                          B      132                                                                                                                                   
   Precuneus                               B      47                                                                                                                                    
   Calcarine sulcus                        B      22                                                                                                                                    
   Cerebellum                              L      380                                                                                                                                   

Abbreviations: Hem., hemisphere; L, left; R, right.

Reported in Montreal Neurologic Institute coordinates (X, Y, and Z).

All comparisons were FDR-corrected (*P*~FDR~ ≤ 0.05).
